



MOLECULAR TESTING

- **EGFR** = Tyrosin Kinase Inhibitor therapy (TKI)
- **MET Amplification** = Resistance to EGFR inhibitors
- **KRAS mutation** = worse prognosis, smokers
- **VEGF**
- **ERBB-2 (HER2)**
- **BRAF**
- **IGF-1R, PIK3CA**

- **TKIs**= Crizotinib & Ceritinib
- **EGFR mutations**
 - More common in **adenocarcinomas** with **lepidic & papillary** patterns
 - Somatic mutations in **exons 18-21 of the tyrosine kinase domain** of EGFR predict **sensitivity to treatment with EGFR (TKIs)**
 - More common in **females, nonsmokers, East Asian ethnicity**
- **K-RAS mutations, BRAF, HER2 mutations**= Downstream of EGFR signaling cascade= mutually exclusive mutations
- **KRAS**= Adenocarcinoma, **mucinous** differentiation, smokers, adverse prognostic factor, resistance to EGFR TKI therapy
- **ALK rearrangements** resulting in **EML4- ALK fusion gene**
 - non small-cell carcinoma of the lung, light or never smokers, younger at presentation.
 - This mutation seems to be mutually exclusive to that of EGFR and KRAS mutations.
 - Detected by FISH, RT-PCR, and IHC.
- **ROS1 rearrangements**: 1-2% of lung ADC; Response to crizotinib; More in light/never smokers, relatively younger pts.

